Form 4: Fortress Biotech Increases MBIO Stake via Dividend

Fortress Biotech, a 10% owner and director of Mustang Bio, Inc., acquired 278,385 shares of common stock as an annual dividend, increasing its beneficial ownership to 536,577 shares.

Summary

• Fortress Biotech, Inc. (the "Reporting Person") acquired 278,385 shares of common stock of Mustang Bio, Inc. (the "Issuer").
• The transaction occurred on January 2, 2026.
• The shares were granted as an annual dividend for 2025 on Fortress Biotech's Class A Preferred Stock.
• The dividend is equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31.
• Following this transaction, Fortress Biotech beneficially owns a total of 536,577 shares of Mustang Bio common stock.
• Fortress Biotech is listed as both a Director and a 10% Owner of Mustang Bio, Inc.

Sentiment

Score: 5

Explanation: The filing reports a routine, expected insider transaction (an annual dividend payment in shares) and does not contain information that would significantly alter the sentiment towards the company or the reporting person.

Positives

• Fortress Biotech increased its beneficial ownership in Mustang Bio by 278,385 shares, strengthening its stake in the company.
• The receipt of shares as a dividend indicates a return on Fortress Biotech's Class A Preferred Stock investment in Mustang Bio.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the details of the completed transaction.

Industry Context

This Form 4 filing details a routine insider transaction, specifically an annual dividend payment in shares, which is common for strategic investors or large shareholders with preferred stock agreements. It reflects a pre-existing financial arrangement between Fortress Biotech and Mustang Bio, rather than a new strategic move or market-driven purchase.

Related Party Transactions

• Fortress Biotech, Inc. is a 10% owner and director of Mustang Bio, Inc. The acquisition of shares by Fortress Biotech from Mustang Bio as an annual dividend constitutes a transaction between related parties.

Stakeholder Impact

• Shareholders of Fortress Biotech: Increased asset base through additional shares in Mustang Bio.
• Shareholders of Mustang Bio: Dilution from the issuance of new shares for the dividend, though this is an expected part of the preferred stock agreement.

Key Dates

Keywords

Fortress Biotech, Mustang Bio, MBIO, SEC Form 4, Insider Transaction, Stock Acquisition, Dividend, Beneficial Ownership, 10% Owner